In which year did the company Eli Lilly prepare two $DNA$ sequences corresponding to $A$ and $B$ chains of human insulin?

Match the following and choose the correct option$-$

Column $I$	Column $II$
$(a)$ Eli Lilly	$(i)$ Bacillus thuringiensis
$(b)$ Bt	$(ii)$ Human insulin
$(c)$ Gene therapy	$(iii)$ Meloidogyne incognita
$(d)$ $\text{RNAi}$	$(iv)$ Adenosine deaminase deficiency

Which new strain of bacteria was produced through biotechnology?

Which of the following peptides is $NOT$ present in mature human insulin?

Statements related to human insulin are given below. Which statement$(s)$ is/are correct about genetically engineered insulin?
$(a)$ Pro-hormone insulin contains an extra stretch of $C$-peptide.
$(b)$ $A$-peptide and $B$-peptide chains of insulin were produced separately in $E. coli$,extracted,and combined by creating disulfide bonds between them.
$(c)$ Insulin used for treating diabetes was extracted from cattle and pigs.
$(d)$ Pro-hormone insulin needs to be processed for converting into a mature and functional hormone.
$(e)$ Some patients develop allergic reactions to the foreign insulin.
Choose the most appropriate answer from the options given below:

Consider the following statements about insulin.
$I.$ Human insulin is made up of $51$ amino acids arranged in two polypeptide chains.
$II.$ The two polypeptide chains are interconnected by two disulphide bridges.
$III.$ In mammals,including humans,insulin is synthesised as a pro-hormone,which contains an extra stretch called the $C$-peptide.
$IV.$ $C$-peptide is not present in the mature insulin.
Which of the statements given above are correct?